• Abstracts and LBCT Rules

    1. Investigators should not submit the same research; applications that appear to be replicate versions of a single study will be rejected.

    2. Follow all instructions for completing the submission. Be sure to structure the content into Background, Methods, Results, and Conclusion sections.

    3. Any abstract presenting data that in whole or part is contained in a Late-Breaking Clinical Trial submission that was accepted to be presented in the SCAI Annual Scientific Sessions general abstract program cannot be presented in the regular program and must be withdrawn if that trial is accepted for presentation as a Late-Breaking Trial.

    4. Abstracts are not eligible for consideration if the data has been presented or published at a U.S. or international meeting held before the SCAI Annual Scientific Sessions.

    5. The SCAI Program Committees endorse the position of the American Association for the Advancement for Science in requiring assurances of the responsible use of animals in research. All submissions for consideration must be in compliance with the guidelines.

    6. Each presenting author will be asked to comply with the SCAI Disclosure Policy. Indication of the relationship, the associated commercial entity and level of support is required for each presenting author. All presenters at SCAI's Annual Scientific Sessions must display a slide at the beginning of their presentation indicating disclosure information as applicable, or that they have nothing to disclose.

    7. The submitter acts on behalf of all co-authors and in submitting an abstract/late-breaking clinical trial, transfers to SCAI the copyright and all other rights in the material comprising the application if the application is accepted. Co-authors reserve the following:
      1. All proprietary rights other than copyright, such as patent rights; and

      2. The right to use all or part of the application in future works of their own. The meeting organizers, as holder of the copyright on the accepted application, reserve all rights of reproduction, distribution, performance, display, and the right to create derivative works in both print and digital formats.